Biontech SE
BNTXToday
+0.29%
5 Days
-3.33%
1 Month
-10.93%
6 Months
-13.53%
Year to Date
-7.30%
1 Year
-15.98%
Key Figures
• BioNTech shares fell after BNT113 failed its progression-free survival endpoint. • Executive insider share sales under pre-arranged trading plans occurred recently. • BioNTech reports an annual revenue of $3.33B and net loss.
• BioNTech and Genentech terminated their Phase 2 autogene cevumeran colorectal cancer trial. • The independent Data Safety Monitoring Board concluded the trial lacked clinical efficacy. • BioNTech reports $3.33B in annual revenue and a net profit of $-1.32B.
• Povetacicept trial met primary endpoint for kidney disease. • Vertex plans BLA submission by March for accelerated review. • Analysts positive on povetacicept's market potential and stock.
• FDA issued warning letter for adverse drug reporting violations. • Analysts downgraded Novo Nordisk due to pipeline and competition concerns. • Company's 2026 guidance projects sales and profit decline.
Biontech SE's Score
Media Coverage
Analyst Rating
Biontech SE Technical Analysis
Financial Indicators
Earnings
Biontech SE Profile
Ownership
| Shareholders | Proportion |
|---|---|
| AT Impf GmbH | 40.05% |
| Medine GmbH | 15.87% |
| Fidelity Management & Research Company LLC | 2.15% |
| T. Rowe Price Investment Management, Inc. | 1.77% |
| Shareholder Types | Proportion |
|---|---|
| Corporation | 56.27% |
| Investment Advisor | 11.90% |
| Investment Advisor/Hedge Fund | 3.82% |
| Research Firm | 2.02% |
Related Instruments
Popular Instruments
